Antiplatelet therapy in myocardial infarction and coronary stent thrombosis
Heestermans, Antonius Adrianus Cornelius Maria

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2010

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Higher efficacy of pre-hospital Tirofiban with longer pre-treatment time to primary PCI

Protection for the negative impact of time delay


Submitted
ABSTRACT

Aims: to evaluate the impact of longer duration of pre-hospital initiated antiplatelet and antithrombotic therapy on outcome in patients with ST-segment elevation myocardial infarction (STEMI).

Methods and results: In this sub-analyses of the Ongoing Tirofiban in Myocardial Evaluation (On-TIME) 2 trial, we studied in 1370 patients the effect of pre-treatment time (time from administering study medication to time of angiography) on complete ST-segment resolution (STR), initial patency and 30-day mortality. Study medication consisted of high dose tirofiban (HDT) or control (placebo or no HDT) on top of high dose clopidogrel, aspirin and unfractionated heparin. Median pre-treatment time was 55 min (44-70). Longer pre-treatment was associated with longer transportation times, longer in hospital delay, longer total ischemic time (all p<0.001) and higher 30-day mortality (3.6% vs. 1.8%, p=0.046). Longer HDT pre-treatment time was independently associated with increased complete STR both before (Odds ratio [OR] 1.51, 95% confidence interval [CI] 0.98-2.32, p=0.06) and after PCI (OR 1.43, 95% CI 1.02-2.02, p=0.039) and with a significantly improved initial TIMI 2 or 3 flow (51.4% vs. 43.4%, p=0.042) and reduced 30-day mortality (2.1% vs. 5.0%, p=0.047) as compared to longer control pre-treatment.

Conclusions: Longer time delay before primary PCI is associated with increased mortality. Pre-treatment with high dose tirofiban however, may compensate for this negative effect by improving ST-segment resolution and initial patency and by reducing mortality. Further studies should be performed to confirm that this is an attractive therapy for patients with longer delays to reperfusion.
INTRODUCTION

Time to reperfusion is of utmost importance in patients presenting with ST-segment elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is the preferred therapy provided it can be performed within 90 minutes after first medical contact\(^1\). Recently the European Society of Cardiology increased this time window from 90 to 120 minutes and therefore many more patients become candidates for treatment with primary PCI\(^2\). Pre-hospital infarct diagnosis either in the ambulance or at a non-PCI referring center offers the possibility to initiate pre-treatment with anti-platelet and anti-thrombotic drugs. So far, guidelines recommend the initiation of aspirin, unfractionated heparin and clopidogrel as soon as possible after first patient contact\(^{[1,2]}\). The Ongoing Tirofiban in Myocardial Evaluation (On-TIME) 2 study showed that the administration of high dose tirofiban (HDT) on top of these agents is associated with improved ST-segment resolution (STR) and clinical outcome\(^3\). With the recent adjustment of the time window to 120 minutes, it is of interest to know whether pre-treatment with triple anti-platelet therapy including HDT is effective in patients with longer delays to PCI as well. Therefore, we evaluated the relationship between the duration of pre-hospital initiated HDT infusion and STR and clinical outcome in the On-TIME 2 trial.

METHODS

Patient population
The On-TIME 2 trial enrolled consecutive patients with STEMI who were candidates for primary PCI. In the run-in phase of the On-TIME 2 trial, two intervention centers in the Netherlands enrolled 414 patients in the ambulance to HDT or no HDT in an open-label randomized fashion. This open-label randomized phase was followed by a double-blind, placebo controlled randomized phase which enrolled 984 patients in an international multicenter study\(^3\). Identical inclusion and exclusion criteria and concomitant treatment regimens were used in both phases from the On-TIME 2 trial, as previously described\(^{[4,5]}\). Patients were randomly assigned to pre-hospital initiation of HDT (tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 18 h) or no HDT in the ambulance in addition to 500 mg of aspirin (Aspegic\(^6\)), 5000 IU unfractionated heparin administered intravenously, and a 600 mg loading dose of clopidogrel. Informed consent was obtained in the ambulance or referring hospital. The study protocol of the On-TIME 2 trial for both the open-label phase and the double-blinded phase was approved by all local ethical committees involved.
In the On-TIME 2 trial all time-intervals were recorded in detail. Total ischemic time was defined as the time from symptom onset to the time of first balloon inflation during primary PCI. Total ischemic time consisted of successive time-intervals. First, time from symptom onset to STEMI diagnosis by the ambulance employees. Second, time from STEMI diagnosis to inclusion, randomization and administering On-TIME 2 study medication. Third, time from initiating study medication to arrival in the hospital. Fourth, time from arrival in the hospital to start angiography and finally the time from start angiography to the first balloon inflation. Duration of pre-treatment with HDT infusion in the present analyses was defined as the time-interval between start study medication to the time of angiography.

We performed analyses on the extent of ST-deviation resolution before angiography in the PCI centre and at 1 h after PCI. Electrocardiograms (ECG) were recorded at 3 time points. First, pre-hospital at the time of STEMI diagnosis by the ambulance employees. Second, before angiography in the cathlab and third, one hour after primary PCI. An independent core lab (Diagram BV, Zwolle, Netherlands) analysed all ECGs as previously described [6,7]. Briefly, the sum of ST-segment deviation in all 12 leads was measured 20 ms after the end of the QRS complex with a calliper. Residual ST segment-deviation was calculated both on the ECG obtained at the catheterization lab before angiography and after primary PCI. ST-segment deviation resolution was calculated from paired ECGs and patients were divided into three groups of ST-segment deviation resolution (complete: ≥ 70% resolution; partial: ≥ 30% but <70% resolution; and no resolution: <30% resolution), as described previously [6,7].

Angiographic assessment was based on the Thrombolysis in Myocardial Infarction (TIMI) flow grade determination of the epicardial infarct related artery (IRA). All angiograms were reviewed by an independent core laboratory (Diagram, Zwolle, the Netherlands), which was blinded to all data apart from the coronary angiograms.

Clinical outcome was assessed at 30 days and at one year. Death was defined as all-cause mortality. Net clinical outcome consisted of the combined incidence of death, recurrent myocardial infarction, urgent target vessel revascularization, stroke and TIMI major bleeding.

Statistical analysis
Statistical analyses were performed on the combined data from the On-TIME 2 trial double-blind and open label phase. Baseline characteristics and outcome of the open-label phase and double-blinded phase were analysed for similarity before combining the data. Univariate analyses were conducted with the chi-square test or Fisher’s exact test for categorical variables, the chi-square for trend for ordinal variables, and the Mann-Whitney U test for continuous variables. We performed multivariate logistic regression
analyses on the dichotomized resolution score (complete versus partial/no resolution) before and after PCI, with a dummy variable to model the 4 different combinations of duration of infusion (≤55 minutes or >55 minutes) and randomization (HDT or control) as the predictor of main interest. We present unadjusted and adjusted models. In the unadjusted model, the dummy variable is the only predictor, with placebo > 55 minutes as a reference category. In the adjusted analysis gender, age (years), current smoking (yes or no) and time from symptom onset to diagnosis (minutes) are included as confounders. Since the adjusted logistic regression analyses have a lower total n due to missing values on some confounders, we performed the unadjusted logistic regression analyses in the group of patients with a valid score on the variables used in the adjusted logistic regression analyses. All p-values were two-sided with significance level p<0.05. The statistical analyses were performed with SPSS for Windows (Rel. 15.0.1.1. 2007. Chicago: SPSS Inc.)

RESULTS

Information on the time-interval between start study medication and angiography was available in 1370 patients (98.0%) and these patients form the basis of this report. The median pre-treatment time as measured from start study medication until the time of angiography was 55 min (IQR 44-70). Baseline characteristics are shown in Table 1. Baseline characteristics were comparable apart from a higher incidence of female and obese patients in those with longer duration of pre-treatment. Longer pre-treatment was associated with a significantly longer distance to the PCI centre, a longer transportation time, a longer door to balloon time and a longer total ischemic time. Overall and subgroup time intervals according to duration of pre-treatment are shown in Figure 1.
### Table 1. Baseline clinical details

<table>
<thead>
<tr>
<th>Characteristics*</th>
<th>Duration pretreatment† ≤ 55 min (n=695)</th>
<th>Duration pretreatment &gt; 55 min (n=675)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>61.3 ± 12.1</td>
<td>62.2 ± 11.7</td>
<td>0.20</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>545 (78.4)</td>
<td>496 (73.5)</td>
<td>0.03</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>231 (33.3)</td>
<td>233 (34.6)</td>
<td>0.60</td>
</tr>
<tr>
<td>Current smoking (%)</td>
<td>323 (47.2)</td>
<td>315 (47.3)</td>
<td>0.98</td>
</tr>
<tr>
<td>Hyperlipidemia (%)</td>
<td>184 (26.6)</td>
<td>166 (24.7)</td>
<td>0.43</td>
</tr>
<tr>
<td>Family history of cardiovascular disease (%)</td>
<td>280 (41.1)</td>
<td>259 (39.3)</td>
<td>0.50</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>77 (11.1)</td>
<td>75 (11.1)</td>
<td>0.99</td>
</tr>
<tr>
<td>Anterior myocardial infarction (%)</td>
<td>272 (43.4)</td>
<td>246 (41.4)</td>
<td>0.49</td>
</tr>
<tr>
<td>Inclusion in ambulance (%)</td>
<td>671 (96.5)</td>
<td>644 (95.4)</td>
<td>0.28</td>
</tr>
<tr>
<td>Killip&gt;1 (%)</td>
<td>83 (12.3)</td>
<td>80 (12.0)</td>
<td>0.87</td>
</tr>
<tr>
<td>Randomization HDT (%)</td>
<td>349 (50.2)</td>
<td>343 (50.8)</td>
<td>0.82</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>26.5 ± 3.7</td>
<td>27.1 ± 3.7</td>
<td>0.002</td>
</tr>
<tr>
<td>Prior myocardial infarction (%)</td>
<td>61 (8.8)</td>
<td>61 (9.1)</td>
<td>0.85</td>
</tr>
<tr>
<td>Prior PCI (%)</td>
<td>58 (8.3)</td>
<td>53 (7.9)</td>
<td>0.75</td>
</tr>
<tr>
<td>Prior coronary bypass surgery (%)</td>
<td>12 (1.7)</td>
<td>16 (2.4)</td>
<td>0.40</td>
</tr>
<tr>
<td>Prior stroke (%)</td>
<td>11 (1.6)</td>
<td>11 (1.6)</td>
<td>0.94</td>
</tr>
<tr>
<td>Time from onset of symptoms to diagnosis and start study medication‡, min</td>
<td>77 (45-147)</td>
<td>78 (45-150)</td>
<td>0.93</td>
</tr>
<tr>
<td>Distance to PCI centre, km</td>
<td>20 (8-33)</td>
<td>33 (20-46)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Total ischemic time, min</td>
<td>151 (117-225)</td>
<td>183 (143-260)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Transportation time, min</td>
<td>28 (15 -43)</td>
<td>39 (23 -54)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Door to balloon time, min</td>
<td>31 (20 -42)</td>
<td>46 (32 -66)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*Percentages exclude patients with missing data. † Duration of pre-treatment is time from start study medication to angiography in minutes. ‡ Study medication consisted of 500 mg of aspirin (Aspegic®), 5000 IU unfractionated heparin administered intravenously, a 600 mg loading dose of clopidogrel and randomization to pre-hospital initiation of high dose tirofiban or placebo. HDT: high dose tirofiban; PCI: percutaneous coronary intervention
Antiplatelet therapy in myocardial infarction

Figure 1. Overall and subgroup time intervals

Effect of duration of pre-treatment on ST segment resolution
Univariate analyses showed that longer pre-treatment duration with HDT was associated with better ST-segment resolution as compared to longer control pretreatment both before and 1 hour after PCI as shown in Figure 2.

ST resolution before PCI in patients pre-treated for more than 55 minutes was significantly better in patients randomized to HDT as compared to the controls (Odds Ratio [OR] 1.59, 95% Confidence Interval [CI] 1.04-2.42, p=0.031), see unadjusted model in Table 2. The same is true for STR 1 hour after PCI (OR 1.47, 95% CI 1.05-2.06, p=0.024). In the adjusted model, STR before PCI tended to be better for patients pre-treated with HDT for more than 55 minutes than for the control patients pre-treated for more than 55 minutes (OR 1.51, 95% CI 0.98-2.32, p=0.06). In the adjusted model for STR 1 hour after PCI, longer pretreatment with HDT gave significantly higher odds on complete STR as compared to the controls (OR 1.43, 95% CI 1.02-2.02, p=0.039). Longer pre-treatment with HDT (> 55 minutes) led to significantly better STR before PCI than shorter pre-treatment with HDT (<=55 minutes) (OR 1.98, 95% CI 1.24-3.15, p=0.004).

The effect of duration of pre-treatment in tertiles on STR before and 1 hour after PCI is depicted in Figure 3. The p value for linear trend for complete STR before PCI was 0.08 and 0.07 for HDT pre-treatment and controls respectively. For complete STR post PCI the p value for linear trend was 0.93 and 0.03 for HDT pre-treatment and controls.
respectively. This demonstrates a significant decreasing trend to achieve complete STR post PCI in the controls with longer delay to angiography, whereas ST resolution remained high for patients pre-treated with HDT.

The number needed to treat with HDT to achieve complete STR in an additional patient before and 1 hour after primary PCI was 23 and 15 respectively.

**Figure 2.** Effect of duration of pre-treatment and randomization to high dose tirofiban or control on ST-segment resolution and 30 day mortality.
### Table 2. Unadjusted and adjusted Odds Ratios for ST-segment resolution before and 1 hour after primary PCI

<table>
<thead>
<tr>
<th>Predictor</th>
<th>ST-segment resolution before PCI (n=1078)</th>
<th>ST-segment resolution after PCI (n=1184)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted</td>
<td>Adjusted</td>
</tr>
<tr>
<td></td>
<td>OR 95% CI</td>
<td>p</td>
</tr>
<tr>
<td>Randomization and duration of infusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>placebo ≤55 minutes</td>
<td>0.76 (0.47-1.23)</td>
<td>0.261</td>
</tr>
<tr>
<td>HDT ≤ 55 minutes</td>
<td>0.79 (0.49-1.29)</td>
<td>0.344</td>
</tr>
<tr>
<td>placebo &gt; 55 minutes (reference)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>HDT &gt; 55 minutes</td>
<td>1.59 (1.04-2.42)</td>
<td>0.031</td>
</tr>
<tr>
<td>Current smoking</td>
<td>1.29 (0.90-1.94)</td>
<td>0.161</td>
</tr>
<tr>
<td>Male sex</td>
<td>1.28 (0.85-1.93)</td>
<td>0.240</td>
</tr>
<tr>
<td>Time from onset of symptoms to diagnosis (15 min)</td>
<td>0.96 (0.94-0.99)</td>
<td>0.004</td>
</tr>
<tr>
<td>Age (10 y)</td>
<td>0.82 (0.71-0.96)</td>
<td>0.012</td>
</tr>
</tbody>
</table>

PCI: percutaneous coronary intervention; HDT: high dose tirofiban
Figure 3. ST-segment resolution before and after primary PCI and TIMI bleeding according to randomization and duration of pre-treatment in tertiles
Effect of duration of pre-treatment on initial TIMI flow, bleeding, mortality and clinical outcome

Initial patency of the IRA as measured by the presence of TIMI 2/3 flow before PCI was not different between HDT or controls with <= 55 minutes pre-treatment (Initial TIMI 3 flow 17.7% vs. 16.5%, p=0.70 and initial TIMI 2/3 flow 36.9% vs. 34.3%, p=0.49). However in patients with > 55 minutes pre-treatment initial patency was significantly better with HDT as compared to the controls (Initial TIMI 3 flow 27.1% vs. 21.8%, p=0.12 and initial TIMI 2/3 flow 51.4% vs. 43.4%, p=0.042).

The incidence of 30 day TIMI major and minor bleeding according to duration of pre-treatment was not different between the HDT group or controls. TIMI major bleeding with <= 55 minutes pre-treatment 2.4% vs. 1.8%, p=0.59 and with > 55 minutes pre-treatment 4.3% vs. 4.1%, p=0.9. TIMI minor bleeding with <= 55 minutes 6.0% vs. 4.2%, p = 0.29 and > 55 minutes 6.1% vs. 4.4%, p=0.34. The incidence of TIMI major and minor bleeding in tertiles is depicted in Figure 3. The p value for linear trend for TIMI major and minor bleeding in patients with HDT pre-treatment was not significant (p=0.52 and p=0.84, respectively.).

Overall, longer time delay between start study medication and angiography was associated with a significantly higher 30 day mortality (3.6% (n=23/646) vs. 1.8% (n=12/670), p=0.046). However, HDT pre-treatment during the longer delay was significantly associated with reduced 30 day mortality as compared to the controls (2.1% (n=7/328) vs. 5.0% (n=16/318), p=0.047), see Figure 2.

Net clinical outcome at 30 days was better in the HDT group as compared to the controls with short (5.1% vs. 9.0%, p=0.049) and longer pre-treatment (9.5% vs. 13.8%, p=0.08).

Relationship of ST resolution and mortality

Patients with complete STR before PCI as well as patients with complete STR 1 hour after PCI had lower 30 day and 1 year mortality. Thirty day and 1 year mortality was 0.5% and 1.1% respectively for patients with complete STR vs. 2.9% and 5.0% respectively for patients with less than complete STR pre-PCI (p=0.063 and p=0.019 respectively).

With regard to STR 1 hour post PCI, 30 day and 1 year mortality was 0.9% and 2.5% for patients with complete STR post PCI vs. 3.7% and 5.4% for patients with less than complete STR post PCI (p<0.001 and p=0.011 respectively).
DISCUSSION

This is the first study that clearly demonstrates that the benefit of pre-treatment with a glycoprotein IIb/IIIa inhibitor is related to the duration of pre-treatment before PCI in patients with STEMI. Patients who were pre-treated with HDT for at least 55 minutes had an approximately 1.5 fold higher odds of having complete STR before and after PCI, as compared to pre-treatment with placebo.

Longer pre-treatment times were associated with longer delay during transportation and in-hospital delay to the cathlab. Not surprisingly, longer transportation time was related to a greater distance to the PCI centre. Figure 1 shows that patient delay (time from the onset of symptoms to first medical contact) is not different between the 2 groups, therefore the difference between the 2 groups is merely reflecting extra time delay due to transportation and logistics.

Despite increasing awareness that the time from first medical contact to reperfusion should be as short as possible, delays are still unavoidable due to local geographic conditions. Recently published data from large scale multicenter trials or registries show a median time from diagnosis or first medical contact until balloon inflation varying between 60 and 300 minutes [3-8]. During this time delay, consisting of time to arrange transportation, transportation itself, preparation of the cathlab and time to angiography, a combination of anti-platelet and anti-thrombotic therapy might be given with the aim to initiate reperfusion and reduce complications during PCI. The international Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) trial showed that full dose lytic therapy did not improve outcome despite improving initial patency of the infarct related vessel [9]. Early, pre-hospital initiation of aspirin and unfractionated heparin has been shown to be associated with improved initial patency [10]. The present substudy from the On-TIME 2 trial showed that a minimum of 55 minutes of pre-treatment with the combination of aspirin, unfractionated heparin, high dose clopidogrel and HDT was associated with a 24% incidence of complete STR before PCI, indicating complete reperfusion in one of every 4 patients pre-treated with HDT for at least 55 minutes. The data on initial patency confirm the effect of early initiation of HDT to establish reperfusion, especially when time to reperfusion is longer. These results show that glycoprotein IIb/IIIa blockers might exert their beneficial effect already during transportation of the patient to the cathlab and not only during PCI. Previous studies [11,12] have demonstrated the very favourable outcome of patients with complete normalisation of ST segment elevation before PCI and these data were confirmed by our findings: patients with complete STR before PCI had a significantly lower one year mortality (p=0.019) as compared to patients with less than complete STR before PCI. In this analysis we found a significantly lower
30 day mortality in patients with longer pre-treatment with triple antiplatelet therapy as compared to longer pre-treatment with dual antiplatelet therapy. This might be explained by an increased incidence of complete STR both before and after PCI and improved initial patency of the IRV with longer triple antiplatelet pre-treatment. Recently other studies also found a beneficial effect of early initiation of a glycoprotein IIb/IIIa blocker. Ortolani and co-workers found that pre-treatment with a IIb/IIIa inhibitor in patients referred to a PCI center was associated with a better clinical outcome [13]. The same was found by Hassan et al, where the early administration of abciximab was associated with an 26% incidence of aborted myocardial infarction [14]. A recent meta-analysis showed improved initial patency and ST resolution in patients pre-treated with a glycoprotein IIb/IIIa blocker [15].

The Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial did not find any benefit of facilitation of PCI with abciximab as compared to abciximab given at the time of PCI [16]. In FINESSE, abciximab was administered relatively late after symptom onset with a median over 160 minutes where in the On-TIME 2 trial study drug was administered very shortly after symptom onset with a median time of only 77 minutes. The combination of rapid STEMI diagnosis early after symptom onset and immediate pre-hospital initiation of triple antiplatelet therapy allowing longer pre-treatment in case of longer transportation times or longer door-to-balloon times seem to be the key to success in the On-TIME 2 trial.

Limitations
There are some aspects of this analysis that merit careful consideration. First, data from two phases of the On-TIME 2 trial with different design (open-label versus double-blind) were combined. However, both study phases had identical in- and exclusion criteria and baseline characteristics and outcome of patients included in both study phases were similar [4]. In addition, an independent core lab and an independent clinical end point committee assessed electrocardiographic, angiographic as well as clinical end points. Second, this analysis was a post-hoc analysis and therefore should be viewed as hypothesis generating and partly expilcatory for the positive results of pre-hospital initiation of HDT in STEMI patients on STR one hour post PCI and mortality in the main On-TIME 2 study.

Conclusions
Longer time delay before primary PCI is associated with increased mortality. Pre-treatment with high dose Tirofiban may compensate for this negative effect by improving ST-segment resolution and initial patency and by reducing mortality. Further studies should be performed to confirm that this is an attractive therapy for patients with longer delays to reperfusion.
REFERENCES


Chapter 4